The following links redirect to external sites which may require subscription access for viewing.

Scientific Publications

Jackman JA, Costa VV, Park SH, Real ALCV, Park JH, Cardozo PL, Ferhan AR, Olmo IG, Poreira TP, Bambirra JL, Queiroz VF, Queiroz-Junior CM, Foureaux G, Souza DG, Ribeiro FM, Yoon BK, Wynendaele E, De Spiegeleer B, Teixeira MM, Cho NJ. Therapeutic Treatment of Zika Virus Infection Using a Brain-Penetrating Antiviral Peptide. Nature Materials 2018; 17, 971–977

Jackman JA, et al. Targeting the Achilles heel of Zika virus and other emerging viral pathogens. Advanced Therapeutics. In press. (2018)

Jackman JA, et al. Deciphering how pore formation causes strain-induced membrane lysis of lipid vesicles. Journal of the American Chemical Society. 138 (4):1406–13. (2016)

Hanson JM, et al. Cholesterol-enriched domain formation induced by viral-encoded, membrane-active amphipathic peptide. Biophysical Journal. 110(1):176-187. (2016)

Tabaei SR, et al. Multi-step compositional remodeling of supported lipid membranes by interfacially active phosphatidylinositol kinases. Analytical Chemistry. 88 (10):5042–5. (2016)

Cho NJ, et al. Reconstitution and functional analysis of a full-length hepatitis C virus NS5B polymerase on a supported lipid bilayer. ACS Central Science. 2 (7):456–466. (2016)

Cho NJ. Envisioning the future of nanotechnology platforms for biomedicine. Small. 12(9):1116. (2016)

Jackman JA, et al. Comparison of complement activation-related pseudoallergy in miniature and domestic pigs: foundation of a validatable immune toxicity model. Nanomedicine: Nanotechnology, Biology, and Medicine. 12(4):933-943. (2015)

Jackman JA, et al. Correlation between membrane partitioning and functional activity in a single lipid vesicle assay establishes design guidelines for antiviral peptides. Small. 11(20): 2372-9. (2015)

Jackman JA, et al. Nanomedicine for infectious disease applications: Innovation towards broad-spectrum treatment of viral infections. Small. 12(9):1133-9. (2015)

Cho NJ, et al. Phosphatidylinositol 4,5-bisphosphate is a ligand of HCV NS5A and mediates viral genome replication. Gastroenterology. 148(3):616-625. (2015)

Jackman JA, et al. Model membrane platforms for biomedicine: case study on antiviral drug development. Biointerphases. 7(18):1-20. (2012)

Cho NJ, et al. Identification of a novel class of HCV inhibitors directed against the nonstructural protein NS4B. Science Translational Medicine. 2(15):1-8. (2010)

Bryson PD, et al. A small molecule inhibits HCV replication and disrupts NS4B subcellular localization. Antiviral Research. 87(1):1-8. (2010)

Cho NJ, et al. Mechanism of an amphipathic α-helical peptide's antiviral activity involves size-dependent virus particle lysis. ACS Chemical Biology. 4(12):1061-7. (2009)

Cho NJ, et al. Creation of lipid partitions by deposition of amphipathic viral peptides. Langmuir. 23(21):10855-63. (2007)

Cho NJ, et al. Binding dynamics of hepatitis C virus' NS5A amphipathic peptide to cell and model membranes. Journal of Virology. 81(12):6682-9. (2007)